Qingyu Wang

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

Ying Cheng, Liang Han, Lin Wu et al. · JAMA · 2022 · 456 citations · Full text

Medicine, Oncology, Pharmacology +17

First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial

Yan Song, Bo Zhang, Dao Xin et al. · Nature Medicine · 2023 · 169 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

Caicun Zhou, Yanping Hu, Ekaterine Arkania et al. · Cancer Cell · 2024 · 60 citations

Medicine, Oncology, Pharmacotherapy +11

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

Binghe Xu, Qingyuan Zhang, Tao Sun et al. · BioDrugs · 2021 · 37 citations · Full text

Medicine, Oncology, Pharmacology +16

Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.

Ying Cheng, Liang Han, Lin Wu et al. · Journal of Clinical Oncology · 2022 · 35 citations

Medicine, Oncology, Pharmacology +17